Lucid Diagnostics Inc. entered into subscription and exchange agreements with accredited investors, resulting in the sale of Series B Convertible Preferred Stock and the exchange of Series A and Series A-1 Preferred Stock for Series B Preferred Stock, generating $18.16 million in gross proceeds.